Page last updated: 2024-12-05

4,4'-methylene bis(2-methylaniline)

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4,4'-methylene bis(2-methylaniline): structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID13283
CHEMBL ID313443
CHEBI ID82343
SCHEMBL ID237201
MeSH IDM0055578

Synonyms (97)

Synonym
CHEMBL313443
chebi:82343 ,
unii-om5xwd3s2i
ec 212-658-8
4,4'-methylene di-ortho-toluidine
3-13-00-00496 (beilstein handbook reference)
3,3'-dimethyl-4,4' diaminodiphenylmethane
om5xwd3s2i ,
o-toluidine,4'-methylenedi-
aniline,4'-methylenebis(2-methyl-
nsc-37146
4,4'-methylenebis[2-methylbenzenamine]
4,4'-methylene bis(2-methylaniline)
838-88-0
4,4'-methylenedi-o-toluidine
me-mda
benzenamine,4'-methylenebis[2-methyl-
bis-4-amino-3-methylfenylmethan
methane, bis[4-amino-3-methylphenyl]-
nsc37146
bis(3-methyl-4-aminophenyl)methane
4,4'-methylenebis[2-methylaniline]
wln: zr b1 d1r dz c1
4,4'-methylene-bis(2-methylaniline)
4,4'-methanediylbis(2-methylaniline)
3,3'-dimethyl-4,4'-diaminodiphenylmethane
mbot
o-toluidine, 4,4'-methylenedi-
nsc 37146
4,4'-methylenebis(o-toluidine)
aniline, 4,4'-methylenebis(2-methyl-
4,4'-methylene di-o-toluidine
4,4'-diamino-3,3'-dimethyldiphenylmethane
2,2'-dimethyl-4,4'-methylenedianiline
brn 0398069
einecs 212-658-8
bis(4-amino-3-methylphenyl)methane
benzenamine, 4,4'-methylenebis(2-methyl-
4,4'-methylenebis(2-methylbenzenamine)
methane, bis(4-amino-3-methylphenyl)-
4,4'-methylenebis(2-methylaniline)
ccris 391
bis-4-amino-3-methylfenylmethan [czech]
MLS000719870
smr000304399
4-(4-amino-3-methylbenzyl)-2-methylphenylamine
TIMTEC1_005368
OPREA1_517776
4-[(4-amino-3-methyl-phenyl)methyl]-2-methyl-aniline
EU-0000098
NCGC00173286-01
AC-10919
HMS1549D22
inchi=1/c15h18n2/c1-10-7-12(3-5-14(10)16)9-13-4-6-15(17)11(2)8-13/h3-8h,9,16-17h2,1-2h3
wecduoxqlaipqw-uhfffaoysa-
4-[(4-amino-3-methylphenyl)methyl]-2-methylaniline
AKOS001483357
D2046
4,4'-methylenebis-o-toluidine
NCGC00173286-02
NCGC00173286-03
STK760092
C19260
dtxcid10867
NCGC00253955-01
dtxsid5020867 ,
tox21_202372
tox21_300201
cas-838-88-0
NCGC00259921-01
CCG-103180
HMS2757J17
4,4'-amino-3,3'-dimethyldiphenylmethane
di(3-methyl-4-aminophenyl)methane
kayabond c 100
methylenebis(2-methylaniline), 4,4'-
SCHEMBL237201
4,4'-methylene-di(o-toluidine)
3,3'-dimethyl-4,4'-diaminodiphenylmethane;4,4'-methylene-bis(2-methylaniline)
W-104130
benzenamine, 4,4'-methylenebis[2-methyl-
4-(4-amino-3-methylbenzyl)-2-methylphenylamine #
SR-01000389448-1
sr-01000389448
mfcd00126963
4,4'-methylene-bis(2-methylaniline), analytical standard
4,4'-diamino-3,3'-dimethyldiphenyl methane
spiro[furo[3,4-b]pyridine-5(7h),4-piperidin]-7-one
FT-0706613
4,4'-diamino-3,3'-dimethyldiphenyl methane 100 microg/ml in acetonitrile
Q229843
D89983
SY052545
4,4 inverted exclamation mark -methylenebis(2-methylaniline)
4,4-methylene-bis(2-methylaniline)
3,3/'-dimethyl-4,4/'-diaminodiphenylmethane
CS-W013022
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
diarylmethaneAny compound containing two aryl groups connected by a single C atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (19)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLS proteinHomo sapiens (human)Potency6.30960.35487.935539.8107AID624170
GLI family zinc finger 3Homo sapiens (human)Potency30.63790.000714.592883.7951AID1259392
AR proteinHomo sapiens (human)Potency39.66830.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743042; AID743063
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency68.58960.000657.913322,387.1992AID1259377
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency34.42840.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency57.80670.000417.946075.1148AID1346795
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency40.47120.001530.607315,848.9004AID1224841; AID1224848; AID1224849; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency61.13060.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency36.72050.000229.305416,493.5996AID1259244; AID1259248; AID743075
67.9K proteinVaccinia virusPotency3.16230.00018.4406100.0000AID720579
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency50.11870.707936.904389.1251AID504333
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency48.96620.001019.414170.9645AID743191
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency50.11870.035520.977089.1251AID504332
aryl hydrocarbon receptorHomo sapiens (human)Potency13.68540.000723.06741,258.9301AID743122
activating transcription factor 6Homo sapiens (human)Potency0.00120.143427.612159.8106AID1159516
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency17.08250.000323.4451159.6830AID743065; AID743067
gemininHomo sapiens (human)Potency1.45810.004611.374133.4983AID624296
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency54.48270.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency54.48270.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (21)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID167927Carcinogenic activity on all sites after oral administration1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Computer-assisted structure-activity studies of chemical carcinogens. Aromatic amines.
AID167951Carcinogenic activity on ear duct after oral administration of the compound; - denotes non carcinogenic activity.1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Computer-assisted structure-activity studies of chemical carcinogens. Aromatic amines.
AID167939Carcinogenic activity on breast after oral administration of the compound1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Computer-assisted structure-activity studies of chemical carcinogens. Aromatic amines.
AID168097Carcinogenic activity on mixed data after oral administration1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Computer-assisted structure-activity studies of chemical carcinogens. Aromatic amines.
AID168084Carcinogenic activity on liver after oral administration1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Computer-assisted structure-activity studies of chemical carcinogens. Aromatic amines.
AID168110Carcinogenic activity on other sites after oral administration1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Computer-assisted structure-activity studies of chemical carcinogens. Aromatic amines.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (36.36)18.7374
1990's0 (0.00)18.2507
2000's1 (9.09)29.6817
2010's5 (45.45)24.3611
2020's1 (9.09)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.74

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.74 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.04 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (16.74)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (9.09%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (90.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]